Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence

Figure 1 Survival analysis based on hierarchical clustering of thioredoxin or thioredoxin-interacting protein correlated genes.

Figure 2 Kaplan-Meier plot of recurrence-free survival and overall survival according to gene expression. Gene expression was measured using quantitative reverse transcription-polymerase chain reaction. Stage III gastric cancer patients were divided into two or three groups according to their gene expression levels. A, B: Survival curves according to thioredoxin (TXN) expression level; C, D: Survival curves according to thioredoxin-interacting protein (TXNIP) expression levels; E, F: Survival curves according to the combination of the TXN and TXNIP expression levels (Group 1: Simultaneous low TXN and high TXNIP expression; Group 2: Neither group 1 nor group 3; Group 3: Simultaneous high TXN and low TXNIP expression). The prognosis was compared across the groups using the log-rank test.

Figure 3 Representative images of immunohistochemical assay (×400). A: The cytoplasm of gastric cancer cells was strongly stained with the anti-thioredoxin (TXN) Ab; B: The cytoplasm of gastric cancer cells was not stained with the anti-TXN Ab; C: The nuclei of gastric cancer cells were strongly stained with the anti-TXN Ab; D; The nuclei of gastric cancer cells were not stained with the anti-TXN Ab; E: The cytoplasm of gastric cancer cells was strongly stained with the anti-thioredoxin-interacting protein (TXNIP) Ab, but the nuclei were not stained; F: The nuclei of gastric cancer cells were strongly stained with the anti-TXNIP Ab, but the cytoplasm was not stained.